Harold J. Wanebo, MD

Emeritus Professor, Surgery

Biography

As emeritus Professor of Surgery in the surgical oncology section at Roger Williams Medical Center, an affiliate of Boston University School of Medicine, Dr. Harold Wanebo spent years training, teaching, and working as a surgical oncologist. He eventually moved into consulting and has delivered over 500 presentations and authored 290 peer reviewed journal articles. His research interests include surgical oncology, hepatobiliary surgery, colorectal surgery and gastrointestinal cancer management and pelvic malignancy surgery. He has been affiliated with numerous professional organizations throughout his academic career including the American College of Surgeons, the American Association for Cancer Research, the New England Surgical Society and many others.

Other Positions

  • Roger Williams Medical Center

Education

  • University of Colorado Boulder, MD
  • Regis College, BS

Publications

  • Published on 10/2/2015

    Stephen AH, Fallon EA, Kalife E, Wanebo H. Radiation-associated sarcoma after recurrent colorectal primary tumor: A complex surgical case. J Surg Oncol. 2015 Nov; 112(6):658-61. PMID: 26430853.

    Read at: PubMed
  • Published on 7/9/2014

    Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014 Oct; 25(10):2036-41. PMID: 25009013.

    Read at: PubMed
  • Published on 4/3/2014

    Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun 1; 20(11):3023-32. PMID: 24700741.

    Read at: PubMed
  • Published on 4/16/2013

    Best C, Calianese D, Szulak K, Cammarata G, Brum G, Carbone T, Still E, Higgins K, Ji F, DI W, Wanebo H, Wan Y. Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death. Oncol Lett. 2013 Jun; 5(6):1854-1858. PMID: 23833655.

    Read at: PubMed
  • Published on 10/25/2012

    Wu CH, Cao C, Kim JH, Hsu CH, Wanebo HJ, Bowen WD, Xu J, Marshall J. Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett. 2012 Nov 14; 12(11):5475-80. PMID: 23030797.

    Read at: PubMed
  • Published on 10/10/2012

    Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M, D'Angelica MI, Kemeny NE. Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis. 2012 Oct; 29(7):821-39. PMID: 23053740.

    Read at: PubMed
  • Published on 9/18/2012

    Karakousis CP, Wanebo H. Pelvic surgery. Int J Surg Oncol. 2012; 2012:287096. PMID: 23029608.

    Read at: PubMed
  • Published on 2/1/2012

    Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J, Kennedy T. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2012 Feb; 35(1):6-12. PMID: 21293244.

    Read at: PubMed
  • Published on 6/7/2011

    White RL, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011 Dec; 18(13):3593-600. PMID: 21647761.

    Read at: PubMed
  • Published on 5/20/2011

    Cong C, Lu S, Shrayer D, Wanebo HJ, Wan Y, Bowen W. The effect of blocking the prosurvival AKT/P13K/mTOR and mutant KRAS-signaling pathways on chemotherapy resistance of pancreatic cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e13514. PMID: 28022938.

    Read at: PubMed

View 240 more publications: View full profile at BUMC

View all profiles